Isabel Ochoa-Navas
机构：National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases
发表论文 3 篇 · 总被引 240 次 · h-index 3
代表论文
- Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus (2021 · Nature Communications · 被引 200)
- Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus (2022 · Annals of the Rheumatic Diseases · 被引 25)
- 183 A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus (2019 · Abstracts · 被引 13)